pioglitazone


Also found in: Dictionary, Wikipedia.

pioglitazone

 [pi″o-glit´ah-zōn]
an agent used in treatment of type 2 diabetes mellitis, decreasing insulin resistance in the peripheral tissues and liver, used orally as the hydrochloride salt.

pioglitazone

(pī′ō-glĭt′ə-zōn′)
n.
A thiazolidinedione drug, C19H20N2O3S, used in its hydrochloride form to treat type 2 diabetes.

pioglitazone

Actos® Endocrinology An oral antidiabetic that ↓ insulin resistance, used to manage type 2 DM; it inhibits hepatic gluconeogenesis, and improves glycemic control while ↓ circulating insulin Adverse effects Edema, ↑ URIs, headaches, myalgias, sinusitis. See Diabetes mellitus.
References in periodicals archive ?
Pioglitazone is the most extensively studied drug for NASH and has demonstrated 'resolution of NASH without worsening of fibrosis' in a Phase 4 trial.
Although studies show that supplementing media with antioxidants can reduce the rate of the developmental block (Goto et al., 1992), the effect of pioglitazone as an antioxidant in mouse embryo development is not yet known.
Based on the pharmacokinetic results, modelling predicts that a 15mg dose of PXL065 may provide a similar exposure of R-pioglitazone as a 45mg dose of the parent drug, pioglitazone (Actos), which suggests it should indicate similar efficacy with an improved safety profile, including reduced weight gain and fluid retention.
Results: After treatment, pioglitazone reduced all the biochemical parameters significantly when compared with diabetic control and negative correlation between glucose and insulin was changed into positive correlation (r value, 0.92) with significant p-value (0.015), while aliskerin caused a significant rise (p-value 0.009) in functional pancreatic [beta] cell mass.
NASH resolved completely in 44% with T2DM and 26% of patients without it, respectively, perhaps indicating that pioglitazone acts slightly differently when patients with NASH have T2DM, according to the investigators.
Pioglitazone is an oral antidiabetic agent and is classified as a peroxisome proliferator-activated receptor-[gamma] (PPAR-[gamma]) agonist (a member of thiazolidinediones), which binds to a specific site on the DNA helix.
The rats were randomly assigned to the sham operation group (SO), SAP model group (SAP), and pioglitazone group (Pi).
Mice were divided into four groups randomly as follows: group I was identified as normal control (uninfection) and group II was treated with pioglitazone only (uninfection + PIO).
In this study, we examined the effects of a novel PPAR-[gamma] agonist, MEKT1, on Pomc expression/ACTH secretion using murine pituitary corticotroph tumor-derived AtT20 cells and compared them with rosiglitazone and pioglitazone. We also examined the effects of MEKT1 on transcription factors Nur77, Nurr1, NeuroD1, and Tpit, which are known to activate Pomc transcription [24-26].
Pioglitazone belongs to the thiazolidinedione class of drugs and was deemed as an insulin sensitizer for the therapy of T2DM [4].
First and second groups were given a daily dose of tab pioglitazone 30mg and gemfibrozil 600mg, respectively, while the third group served as the healthy control.
Metformin is not effective in fatty liver disease but drugs like pioglitazone works.